coteau ARQ.

AXSM

AXSM
$145.04
−$11.03 (7.07%) Oct 23 close
Sector n/a CompareTechnicals
1M3M6M1Y2Y
-5%+21%+46%+71%+97%Oct 2025Oct 2026Apr 202652w high $255.1752w low $127.06
AXSMSPY
Wall St. Highest PT $323.76 (+123.2%) Wall St. Avg PT $265.38 (+83.0%)
$127$206$285$364$443POC $187Hi $324Avg $265
Underwater Drawdown %Max DD -43.2%Current -43.2%
0.0%-43.2%
Relative Strength vs SPY-3.2% vs SPYUnderperforming
+98%0%-98%
1W
−$12.10 (7.70%)
1M
−$48.41 (25.02%)
3M
−$95.96 (39.82%)
6M
−$40.92 (22.00%)
YTD
−$37.60 (20.59%)
1Y
+$17.98 (14.15%)

Chart

Loading live chart…

Ratings & dials

1m · 5m · 15m · 1h · 4h · 1D

Analyst & Morningstar ratings

Consensus · Targets · Morningstar
Wall Street & Morningstar coverage
Wall Street consensusNo covering analysts on file for AXSM
Analyst price targetsNo target range on file
Morningstar star ratingNot rated
Checked Wall Street & Morningstar feeds · All analyst rating changes ›

Third-party ratings, not Coteau's views.

Key stats & company

52-week range$127.06 – $255.17

What they do

Axsome Therapeutics, Inc., a biopharmaceutical company, develops and delivers novel therapies for the management of central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist, sigma-1 receptor agonist. It also develops AXS-05 (dextromethorphan-bupropion).

Healthcare · Biotechnology
Valuation and fundamentals

Valuation & fundamentals

Loading the valuation from SEC filings…

For information only · Important disclosures

Grades vs sector

No sector grades for AXSM yet. Grades rank S&P 1500 stocks within their sector and refresh after each daily data run, so a stock outside that index or newly covered has none.

Systematic Models

Not held by any of our 7 live models right now.

Quality Growth
Outside this model's universe or screens
 Momentum Top 15
Outside this model's universe or screens
 Momentum Blend
Not in the current book
 New Highs Growth
Outside this model's universe or screens
 Coteau Barbell Momentum & T-Bill Shield
Outside this model's universe or screens
 Coteau Physical AI Grid & Power
Outside this model's universe or screens
 Coteau Long Book
Not in the current book

Earnings & events

AXSM earningsNext report in 9 days
Next report · quarter Sep 2026
Mon Nov 2, 2026Before the open
EPS consensus-$0.64
Revenue consensus–
Last 4 quarters · EPS vs estimate
Aug 10, 2026-$0.99est -$0.78−26.9%Below estimates
May 4, 2026-$1.26est -$0.86−46.0%Below estimates
Feb 23, 2026-$0.56est -$0.73+23.6%Above estimates
Nov 3, 2025-$0.94est -$0.90−4.2%Below estimates

In line = within 1% of the estimate.

Source: Yahoo Finance · report time: Nasdaq earnings calendar · refreshed 2026-10-21 18:20:22 ET
24-1125-0225-0525-0825-1126-0226-0526-08-1.540.00
EstimateActual (beat)Actual (miss)

News & catalysts

More news
No recent headlines.
Insider trades
Jacobson Mark L.
Chief Operating Officer · 2026-09-03
Sell
$2.1M
Tabuteau Herriot
Director, Chief Executive Officer, 10% owner · 2026-08-06
Sell
$997.0K
Tabuteau Herriot
Director, Chief Executive Officer, 10% owner · 2026-08-05
Sell
$9.5M

Stats refreshed 2026-10-21 18:20:22 ET from Yahoo Finance (yfinance). "–" means the data isn't available. Refresh now

Morning Brief (8 AM ET) & Market Close (4:30 PM ET), weekdays

Indexes, sectors, biggest movers, rates, top news, Coteau model changes and what's ahead. Free, two short emails each weekday.

Editions

Free. Not investment advice. Unsubscribe anytime.

coteau

Free to use. No card, no ads, no auto-renew.

Independent research · Not investment advice · Hypothetical unless marked Live · Data: Yahoo Finance (15-min delayed), SEC EDGAR, House Clerk · Important disclosures · Contact desk@coteau.app

How it worksOur promiseTermsPrivacyData statusSend feedback
Coteau 0.9 · Oct 21, 2026